Quaker BioVentures is the famous VC, which was founded in 2002. The main department of described VC is located in the Philadelphia. The venture was found in North America in United States.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Quaker BioVentures, startups are often financed by Domain Associates, Investor Growth Capital Limited, Three Arch Partners. The meaningful sponsors for the fund in investment in the same round are Johnson & Johnson Development Corporation, Intersouth Partners, Investor Growth Capital Limited. In the next rounds fund is usually obtained by Johnson & Johnson Development Corporation, Investor Growth Capital Limited, Domain Associates.
Besides them, we counted 13 critical employees of this fund in our database.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Celator Pharmaceuticals, Rapid Micro Biosystems, TetraLogic Pharmaceuticals Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Health Diagnostics.
The higher amount of exits for fund were in 2017. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. This Quaker BioVentures works on 1 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.
Funds with similar focus
|BENGBU INVESTMENT GROUP CO.,LTD||-|
|Capital Development Investment Fund||Beijing, Beijing, China|
|Dongling Yuda Capital||-|
|eLong.com||Beijing, Beijing, China|
|Huaxinke Intelligent Manufacturing Technology||China, Guangdong, Guangzhou|
|Jupiter Telecommunications (J:COM)||Japan, Tokyo|
|NN Group||The Hague, The Netherlands, Zuid-Holland|
|NOMO Ventures||California, San Francisco, United States|
|Rive Private Investment||Geneva, Geneve, Switzerland|
|Shenzhen Qianhai Jiayang Venture Capital||China, Guangdong, Shenzhen|
|Shenzhen Tasen Touzi Konggu Co., Ltd.||China, Guangdong, Shenzhen|
|Social Family Group||Australia, New South Wales, North Sydney|
|South River Capital||China, Shanghai|
|StudiVZ||Berlin, Berlin, Germany|
|Teca Partners||New York, New York, United States|
|Trilogy Equity Partners||Bellevue, United States, Washington|
|Watchfire Ventures||California, Santa Barbara, United States|
|Zhongguo Jiankang Chanye Touzi Jijin||Beijing, Beijing, China|
|$6M||20 Mar 2019||Pittsburgh, Pennsylvania, United States|
|$34M||27 Apr 2015||Pennsylvania, United States|
|$67M||23 Sep 2013||Rhode Island, United States|
|$20M||29 Apr 2013||Massachusetts, United States|
|$15M||05 Sep 2012||Radnor Township, Pennsylvania, United States|
|$28M||16 Mar 2012||Philadelphia, Pennsylvania, United States|
|$35M||27 Jun 2011||Maryland, United States|
|$30M||16 May 2011||Pennsylvania, United States|
|$37M||25 Jan 2011||Massachusetts, United States|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.